• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13E3 filed by Walgreens Boots Alliance Inc.

    4/14/25 7:29:50 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email
    SC 13E3 1 d946494dsc13e3.htm SC 13E3 SC 13E3
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13E-3

    RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(E)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

     

    Walgreens Boots Alliance, Inc.

    (Name of the Issuer)

     

     

    Walgreens Boots Alliance, Inc.

    Blazing Star Parent, LLC

    Blazing Star Merger Sub, Inc.

    Sycamore Partners III, L.P.

    Sycamore Partners III-A, L.P.

    Sycamore Partners Wing Co-Invest, L.P.

    Sycamore Partners III GP, L.P.

    Sycamore Partners III GP, Ltd.

    Blazing Star CCX Superco, Inc.

    Blazing Star IA Parent, LLC

    Blazing Star Shields Superco II, LLC

    Blazing Star Investors, LLC

    Blazing Star Boots Superco (Jersey) Limited

    Blazing Star Retail Blocker Buyer, LLC

    Blazing Star Office Blocker Buyer, LLC

    Blazing Star DC Blocker Buyer, LLC

    Blazing Star Excluded Property Blocker Buyer, LLC

    Alliance Santé Participations S.A.

    Stefano Pessina

    (Names of Persons Filing Statement)

     

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    931427108

    (CUSIP Number of Class of Securities)

     

     

     

    Walgreens Boots Alliance, Inc.

    108 Wilmot Road

    Deerfield, Illinois 60015

    (847) 315-3700

    Attn: Lanesha Minnix, Executive Vice President and Global Chief Legal Officer

     

    Blazing Star Parent, LLC

    Blazing Star Merger Sub, Inc.

    Sycamore Partners III, L.P.

    Sycamore Partners III-A, L.P.

    Sycamore Partners Wing Co-Invest, L.P.

    Sycamore Partners III GP, L.P.

    Sycamore Partners III GP, Ltd.

    Blazing Star CCX Superco, Inc.

    Blazing Star IA Parent, LLC

    Blazing Star Shields Superco II, LLC

    Blazing Star Investors, LLC

    Blazing Star Boots Superco (Jersey) Limited

    Blazing Star Retail Blocker Buyer, LLC

    Blazing Star Office Blocker Buyer, LLC

    Blazing Star DC Blocker Buyer, LLC

    Blazing Star Excluded Property Blocker Buyer, LLC

    9 West 57th Street, 31st Floor

    New York, NY 10019

    (212) 796-8500

    Attn: Stefan Kaluzny

     

    Alliance Santé Participations S.A.

    14, avenue du X Septembre

    L-2550 Luxembourg

    Grand Duchy of Luxembourg

    +352 27 99 01 03

    Attn: Simone Retter

      

    Stefano Pessina

    24, boulevard du Ténao

    98000 Monaco

    +377 99 99 60 40

     

    (Name, Address, and Telephone Numbers of Person Authorized to Receive Notices and Communications on Behalf of the Persons Filing Statement)

    With copies to

     

    Joshua N. Korff, P.C.

    Rachael G. Coffey, P.C.

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, New York 10022

    (212) 446-4800

     

    Brian Wolfe

    Darren Schweiger

    Michael Senders

    Davis Polk & Wardwell LLP

    450 Lexington Avenue

    New York, New York 10017

    (212) 450-10017

     

    Jeffrey J. Rosen

    Gordon S. Moodie

    Emily F. Huang

    Debevoise & Plimpton LLP

    66 Hudson Boulevard

    New York, New York 10001

    (212) 909-6000

      

    Ben Burman Avocat EURL

    69, avenue Victor Hugo

    75116 Paris, France

    +33 1 45 02 19 19

     

     

    This statement is filed in connection with (check the appropriate box):

     

    a. 

      ☒   The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934.

    b. 

      ☐   The filing of a registration statement under the Securities Act of 1933.

    c. 

      ☐   A tender offer.

    d. 

      ☐   None of the above.

    Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☒

    Check the following box if the filing is a final amendment reporting the results of the transaction: ☐

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of this transaction, passed upon the merits or fairness of this transaction or passed upon the adequacy or accuracy of the disclosure in this transaction statement on Schedule 13E-3. Any representation to the contrary is a criminal offense.

     

     
     


    Introduction

    This Transaction Statement on Schedule 13E-3 (this “Transaction Statement”) is being filed with the U.S. Securities and Exchange Commission (the “SEC”) pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”), by (1) Walgreens Boots Alliance, Inc., a Delaware corporation (“WBA” or the “Company”); (2) Blazing Star Parent, LLC, a Delaware limited liability company (“Parent”), (3) Blazing Star Merger Sub, Inc. (“Merger Sub”), a Delaware corporation, (4) Sycamore Partners III, L.P., a Cayman Islands exempted limited partnership (“Sycamore Partners III, L.P.”), (5) Sycamore Partners III-A, L.P., a Cayman Islands exempted limited partnership (“Sycamore Partners III-A, L.P.”), (6) Sycamore Partners Wing Co-Invest, L.P., a Delaware limited partnership (“Sycamore Partners Wing Co-Invest, L.P.”), (7) Sycamore Partners III GP, L.P., a Cayman limited partnership (“Sycamore Partners III GP, L.P.”), (8) Sycamore Partners III GP, Ltd., a Cayman limited company (“Sycamore Partners III GP, Ltd.”), (9) Blazing Star CCX Superco, Inc., a Delaware corporation (“Blazing Star CCX Superco, Inc.”), (10) Blazing Star IA Parent, LLC, a Delaware limited liability company (“Blazing Star IA Parent, LLC”), (11) Blazing Star Shields Superco II, LLC, a Delaware limited liability company (“Blazing Star Shields Superco II, LLC”), (12) Blazing Star Investors, LLC, a Delaware limited liability company (“Blazing Star Investors, LLC”), (13) Blazing Star Boots Superco (Jersey) Limited, a Jersey private limited company (“Blazing Star Boots Superco (Jersey) Limited”), (14) Blazing Star Retail Blocker Buyer, LLC, a Delaware limited liability company (“Blazing Star Retail Blocker Buyer”), (15) Blazing Star Office Blocker Buyer, LLC, a Delaware limited liability company (“Blazing Star Office Blocker Buyer”), (16) Blazing Star DC Blocker Buyer, LLC, a Delaware limited liability company (“Blazing Star DC Blocker Buyer”), (17) Blazing Star Excluded Property Blocker Buyer, LLC, a Delaware limited liability company (“Blazing Star Excluded Property Blocker Buyer”), (18) Alliance Santé Participations S.A., a Luxembourg société anonyme, and (19) Stefano Pessina, a Monégasque citizen (each of (1) through (19) a “Filing Person,” and collectively, the “Filing Persons”).

    This Transaction Statement relates to the Agreement and Plan of Merger, dated as of March 6, 2025 (as it may be amended from time to time, the “Merger Agreement”), by and among the Company, Parent, Merger Sub and the other affiliates of Parent named therein, pursuant to which, subject to the terms and conditions set forth therein and among other things, Merger Sub will be merged with and into the Company with the Company surviving such merger as a wholly owned subsidiary of Parent (the “Merger”).

    Upon the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of the Company’s common stock, par value $0.01 per share (“Company Common Stock”) issued and outstanding immediately prior to the Effective Time (other than any shares of Company Common Stock that are held by the Company as treasury stock or owned by Parent, Merger Sub or any other affiliate thereof (the “Excluded Shares”), or any shares of Company Common Stock as to which appraisal rights have been properly exercised in accordance with the General Corporation Law of the state of Delaware (the “DGCL”) (the “Dissenting Shares”)) will be automatically converted into the right to receive (a) cash in an amount equal to $11.45, without interest thereon and subject to all applicable withholding (the “Per Share Cash Consideration”), and (b) one divested asset proceed right (each, a “Divested Asset Proceed Right” or “DAP Right”) issued by Parent or one of its affiliates subject to and in accordance with the Divested Asset Proceed Rights Agreement (the “Per Share DAP Right Consideration” and, collectively with the Per Share Cash Consideration, the “Per Share Consideration”). Following the completion of the Merger, the shares of Company Common Stock will no longer be publicly traded, and holders of such shares of Company Common Stock that have been converted into the right to receive the Per Share Consideration will cease to have any ownership interest in the Company.

    In connection with the entry into the Merger Agreement, Stefano Pessina and Alliance Santé Participations S.A., a Luxembourg société anonyme, who are referred to in this Transaction Statement as the “SP Investors,” entered into a voting agreement (the “Voting Agreement”), with the Company and Parent. The shares beneficially owned by the SP Investors represent, in the aggregate, approximately 17% of the outstanding voting power of the Company’s capital stock as of March 6, 2025. The SP Investors have agreed, on the terms and subject to the conditions set forth in the Voting Agreement, to vote their shares of the Company’s capital stock owned by them: (1) in favor of the adoption of the Merger Agreement and the approval of the Merger and the


    other transactions contemplated by the Merger Agreement (the “Transactions”), and to vote against, among other things, any Acquisition Proposal (as defined in the Merger Agreement) or other proposal made in opposition to or in competition with the Merger Agreement and the Merger. The Voting Agreement will terminate on the earliest to occur of (i) the valid termination of the Merger Agreement in accordance with its terms and (ii) the Effective Time.

    Also in connection with the entry into the Merger Agreement, the SP Investors entered into a reinvestment agreement (the “Reinvestment Agreement”) with Parent, pursuant to which the SP Investors agreed, on the terms and subject to the conditions set forth in the Reinvestment Agreement, to reinvest the aggregate Per Share Cash Consideration received by the SP Investors and an incremental cash investment, in each case, to purchase, immediately following the closing of the Merger, new equity interests in the Topcos (as defined in the Proxy Statement). Immediately following the closing of the transactions contemplated by the Reinvestment Agreement, the proportion of equity at each Topco, held by the SP Investors, on the one hand, and Sycamore and its affiliates, on the other hand, will be the same at each Topco. The Reinvestment Agreement will terminate either (i) upon the mutual written consent of Parent, the SP Investors and the Company or (ii) automatically if the Merger Agreement is terminated in accordance with its terms.

    The Company’s board of directors (the “Board”), with Stefano Pessina and John Lederer (the “Recused Directors”) recused from the deliberations and approval, unanimously (1) determined that it is fair to, and in the best interests of the Company and the Company’s stockholders (including the unaffiliated stockholders (as defined below)), and declared it advisable, to enter into the Merger Agreement and certain other transaction documents, in each case, upon the terms and subject to the conditions set forth therein, (2) approved the execution and delivery of the Merger Agreement and certain other transaction documents by the Company, the performance by the Company of its covenants and other obligations thereunder, and the consummation of the Merger upon the terms and subject to the conditions set forth therein, (3) resolved to recommend that the Company’s stockholders adopt and approve the Merger Agreement in accordance with the DGCL; and (4) directed that the adoption and approval of the Merger Agreement be submitted for consideration by the Company’s stockholders at a meeting thereof.

    The approval of the proposal to adopt and approve the Merger Agreement, which we refer to as the “Merger Agreement Proposal,” requires both the affirmative vote of (a) the holders of a majority of the outstanding shares of Company Common Stock entitled to vote on such matter at the Special Meeting, which we refer to as the “Delaware law vote condition,” and (b) the holders of a majority of the outstanding shares of Company Common Stock held by the unaffiliated stockholders cast on such matter at the Special Meeting, which we refer to as the “unaffiliated vote condition.” The unaffiliated stockholders are the holders of shares of Company Common Stock other than Stefano Pessina, John Lederer, Parent and any of their respective affiliates.

    Concurrently with the filing of this Transaction Statement, the Company is filing with the SEC a preliminary proxy statement (the “Proxy Statement”) under Regulation 14A of the Exchange Act, pursuant to which the Board is soliciting proxies from stockholders of the Company in connection with the Merger. The Proxy Statement is attached hereto as Exhibit (a)(1). A copy of the Merger Agreement is attached to the Proxy Statement as Annex A and is incorporated herein by reference. As of the date hereof, the Proxy Statement is in preliminary form, and is subject to completion or amendment. Terms used but not defined in this Transaction Statement have the meanings assigned to them in the Proxy Statement.

    Pursuant to General Instruction F to Schedule 13E-3, the information in the Proxy Statement, including all annexes thereto, is expressly incorporated by reference herein in its entirety, and responses to each item herein are qualified in their entirety by the information contained in the Proxy Statement and the annexes thereto. The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the Proxy Statement of the information required to be included in response to the items of Schedule 13E-3.

    While each of the Filing Persons acknowledges that the Merger is a going private transaction for purposes of Rule 13E-3 under the Exchange Act, the filing of this Transaction Statement shall not be construed as an


    admission by any Filing Person, or by any affiliate of a Filing Person, that the Company is “controlled” by any of the Filing Persons and/or their respective affiliates.

    The information concerning the Company contained in, or incorporated by reference into, this Transaction Statement and the Proxy Statement was supplied by the Company. Similarly, all information concerning each other Filing Person contained in, or incorporated by reference into, this Transaction Statement and the Proxy Statement was supplied by such Filing Person. No Filing Person, including the Company, is responsible for the accuracy of any information supplied by any other Filing Person.

     

    Item 1.

    Summary Term Sheet

    Regulation M-A Item 1001

    The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

     

    Item 2.

    Subject Company Information

    Regulation M-A Item 1002

    (a) Name and address. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Parties to the Merger—The Company”

    (b) Securities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Questions and Answers About the Special Meeting and the Merger—Who can vote at the Special Meeting?”

    “The Special Meeting—Record Date and Quorum”

    “Other Important Information Regarding the Company”

    (c) Trading market and price. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Other Important Information Regarding the Company—Market Price of Common Stock and Dividends”

    (d) Dividends. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “The Merger Agreement—Covenants Relating to the Conduct of the Company’s Business”

    “Other Important Information Regarding the Company—Market Price of Common Stock and Dividends”

    (e) Prior public offerings. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Other Important Information Regarding the Company—Prior Public Offerings”

    (f) Prior stock purchases. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Other Important Information Regarding the Company—Certain Transactions in the Shares of Common Stock”


    Item 3.

    Identity and Background of Filing Person

    Regulation M-A Item 1003(a) through (c)

    (a) – (b) Name and Address of Each Filing Person; Business and Background of Entities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet—Parties to the Merger”

    “Parties to the Merger”

    “Other Important Information Regarding the Company—Directors and Executive Officers of the Company”

    “Other Important Information Regarding the Sycamore Entities” “Where You Can Find More Information”

    (c) Business and Background of Natural Persons.

    “Other Important Information Regarding the Company—Directors and Executive Officers of the Company”

    “Other Important Information Regarding the Sycamore Entities”

     

    Item 4.

    Terms of the Transaction

    Regulation M-A Item 1004(a) and (c) through (f)

    (a) Material terms.

     

      (1)

    Tender offer. Not applicable.

     

      (2)

    (i) – (vii) Merger or Similar Transactions.

    The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities of the Merger”

    “Special Factors—Opinions of the Financial Advisors to the Board”

    “Special Factors—Certain Unaudited Prospective Financial Information”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Interests of the Executive Officers and Non-Employee Directors of the Company in the Merger”

    “Special Factors—Material U.S. Federal Income Tax Consequences of the Merger”

    “Special Factors—Effective Time of the Merger”

    “Special Factors—Payment of Per Share Consideration”

    “Special Factors—Accounting Treatment”

    “The Merger Agreement—Closings and Effective Time of the Merger”

    “The Merger Agreement—Payment Procedures”

    “The Merger Agreement—Treatment of Company Stock Awards and Employee Purchase Plans”

    “The Merger Agreement—Indemnification”

    “The Merger Agreement—Employee Benefits Matters”

    “The Merger Agreement—Proxy Statement; Company Stockholders’ Meeting; Schedule 13E-3”

    “The Merger Agreement—Conditions to the Merger”

    “The Voting Agreement”

    “The Special Meeting—Vote Required”

    “The Merger-Related Compensation Proposal”


    Annex A: Agreement and Plan of Merger

    (c) Different terms. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Interests of the Executive Officers and Non-Employee Directors of the Company in the Merger”

    “The Merger Agreement—Payment Procedures”

    “The Merger Agreement—Treatment of Company Stock Awards and Employee Purchase Plans”

    “The Merger Agreement—Indemnification”

    “The Merger Agreement—Employee Benefits Matters”

    “The Voting Agreement”

    “The Merger-Related Compensation Proposal”

    Annex A: Agreement and Plan of Merger

    Annex D: Voting Agreement

    (d) Appraisal rights. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Questions and Answers About the Special Meeting and the Merger—Am I entitled to rights of appraisal under the DGCL?”

    “Special Factors—Appraisal Rights”

    “The Merger Agreement—Appraisal Rights”

    (e) Provisions for unaffiliated security holders. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Provisions for Unaffiliated Stockholders”

    (f) Eligibility for listing or trading. Not applicable.

     

    Item 5.

    Past Contacts, Transactions, Negotiations and Agreements

    Regulation M-A Item 1005(a) through (c) and (e)

    (a) Transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Special Factors—Background of the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Interests of the Executive Officers and Non-Employee Directors of the Company in the Merger”

    “Special Factors—Financing of the Merger”

    “The Merger Agreement”

    “The Divested Asset Proceed Rights Agreement”

    “The Voting Agreement”

    “The Reinvestment Agreement”

    “The Merger-Related Compensation Proposal”

    “Other Important Information Regarding the Company—Certain Transactions in the Shares of Common Stock”


    Annex A: Agreement and Plan of Merger

    Annex D: Voting Agreement

    Annex E: Reinvestment Agreement

    (b) – (c) Significant corporate events; Negotiations or contacts. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Interests of the Directors and the Executive Officers of the Company in the Merger”

    “Special Factors—Financing of the Merger”

    “The Merger Agreement”

    “The Divested Asset Proceed Rights Agreement”

    “The Voting Agreement”

    “The Reinvestment Agreement”

    Annex A: Agreement and Plan of Merger

    Annex D: Voting Agreement

    Annex E: Reinvestment Agreement

    (e) Agreements involving the subject company’s securities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Plans for the Company After the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Financing of the Merger”

    “The Merger Agreement”

    “The Divested Asset Proceed Rights Agreement”

    “The Voting Agreement”

    “The Reinvestment Agreement”

    “The Special Meeting—Vote Required”

    “The Merger-Related Compensation Proposal”

    “Other Important Information Regarding the Company—Certain Transactions in the Shares of Common Stock”

    Annex A: Agreement and Plan of Merger

    Annex D: Voting Agreement

    Annex E: Reinvestment Agreement

     

    Item 6.

    Purposes of the Transaction and Plans or Proposals

    Regulation M-A Item 1006(b) and (c)(1) through (8)

    (b) Use of securities acquired. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Special Factors—Plans for the Company After the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Certain Effects of the Merger for Parent”

    “Special Factors—Certain Effects on the Company if the Merger Is Not Completed”

    “Special Factors—Financing of the Merger”


    “Special Factors—Payment of Per Share Consideration”

    “Special Factors—Interests of the Executive Officers and Non-Employee Directors of the Company in the Merger”

    “The Merger Agreement—Treatment of Company Stock Awards and Employee Stock Purchase Plan”

    “The Reinvestment Agreement”

    “Other Important Information Regarding the Company—Market Price of Common Stock and Dividends”

    “Delisting and Deregistration of Common Stock”

    Annex A: Agreement and Plan of Merger

    Annex E: Reinvestment Agreement

    (c) (1) – (8) Plans. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purpose and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Plans for the Company After the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Certain Effects of the Merger for Parent”

    “Special Factors—Certain Effects on the Company if the Merger Is Not Completed”

    “Special Factors—Interests of the Executive Officers and Non-Employee Directors of the Company in the Merger”

    “Special Factors—Financing of the Merger”

    “The Merger Agreement—The Merger; Directors and Officers” “The Merger Agreement—Treatment of Company Stock Awards and Employee Purchase Plans”

    “The Merger Agreement—Covenants Relating to the Conduct of the Company’s Business”

    “The Divested Asset Proceed Rights Agreement”

    “The Voting Agreement”

    “The Reinvestment Agreement”

    “Other Important Information Regarding the Company —Market Price of Common Stock and Dividends”

    “Other Important Information Regarding the Company—Directors and Executive Officers of the Company”

    “Delisting and Deregistration of Common Stock”

    Annex A: Agreement and Plan of Merger

    Annex D: Voting Agreement

    Annex E: Reinvestment Agreement

     

    Item 7.

    Purposes, Alternatives, Reasons and Effects

    Regulation M-A Item 1013

    (a) Purposes. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors— Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Plans for the Company After the Merger”

    “Special Factors—Certain Effects of the Merger”


    (b) Alternatives. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Opinions of the Financial Advisors to the Board”

    (c) Reasons. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Opinions of the Financial Advisors to the Board”

    “Special Factors—Certain Unaudited Prospective Financial Information”

    “Special Factors—Certain Effects of the Merger”

    Annex B: Opinion of Centerview

    Annex C: Opinion of Morgan Stanley

    (d) Effects. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Opinions of the Financial Advisors to the Board”

    “Special Factors—Plans for the Company After the Merger”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Certain Effects of the Merger for Parent”

    “Special Factors—Certain Effects on the Company if the Merger Is Not Completed”

    “Special Factors—Interests of Directors and Executive Officers of the Company in the Merger”

    “Special Factors—Appraisal Rights”

    “Special Factors—Material U.S. Federal Income Tax Consequences of the Merger”

    “Special Factors—Accounting Treatment”

    “Special Factors—Financing of the Merger”

    “Special Factors—Fees and Expenses”

    “Special Factors—Payment of Per Share Consideration”

    “The Merger Agreement—The Merger; Directors and Officers”

    “The Merger Agreement—Treatment of Company Stock Awards and Employee Purchase Plans”

    “The Merger Agreement—Covenants Relating to the Conduct of the Company’s Business”

    “The Merger Agreement—Indemnification”

    “The Merger Agreement—Employee Benefits Matters”

    “Other Important Information Regarding the Company—Market Price of Common Stock and Dividends”

    “Delisting and Deregistration of Common Stock”

    Annex A: Agreement and Plan of Merger

    Annex B: Opinion of Centerview

    Annex C: Opinion of Morgan Stanley


    Item 8.

    Fairness of the Transaction

    Regulation M-A Item 1014

    (a) – (b) Fairness; Factors considered in determining fairness. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Opinions of the Financial Advisors to the Board”

    “Special Factors—Summary of Presentations Provided by Centerview and Morgan Stanley”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Interests of Executive Officers and Directors of the Company in the Merger”

    Annex B: Opinion of Centerview

    Annex C: Opinion of Morgan Stanley

    (c) Approval of security holders. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “The Merger Agreement—Proxy Statement; Company Stockholders’ Meeting; Schedule 13E-3”

    “The Merger Agreement—Conditions to the Merger”

    “The Special Meeting”

    “The Merger Agreement Proposal”

    Annex A: Agreement and Plan of Merger

    (d) Unaffiliated representative. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Provisions for Unaffiliated Stockholders”

    (e) Approval of directors. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Opinions of the Financial Advisors to the Board”

    “Special Factors—Interests of the Executive Officers and Non-Employee Directors of the Company in the Merger”

    “The Merger Agreement Proposal”


    (f) Other offers. Not applicable.

     

    Item 9.

    Reports, Opinions, Appraisals and Negotiations

    Regulation M-A Item 1015

    (a) – (b) Report, opinion or appraisal; Preparer and summary of the report, opinion or appraisal. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Opinions of the Financial Advisors to the Board”

    “Special Factors—Summary of Presentations Provided by Centerview and Morgan Stanley”

    “Where You Can Find More Information”

    Annex B: Opinion of Centerview

    Annex C: Opinion of Morgan Stanley

    (c) Availability of documents. The reports, opinions or appraisals referenced in this Item 9 will be made available for inspection and copying at the principal executive offices of the Company during its regular business hours by any interested equity security holder of the Company or representative who has been so designated in writing.

     

    Item 10.

    Source and Amounts of Funds or Other Consideration

    Regulation M-A Item 1007

    (a) – (b), (d) Source of funds; Conditions; Borrowed Funds. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Special Factors—Financing of the Merger”

    “The Merger Agreement—Financing; Cooperation with Debt Financing”

    “The Reinvestment Agreement”

    Annex E: Reinvestment Agreement

    (c) Expenses. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Certain Effects on the Company if the Merger Is Not Completed”

    “Special Factors—Fees and Expenses”

    “The Merger Agreement—Termination”

    “The Merger Agreement—Termination Fees; Reimbursement of Expenses”

     

    Item 11.

    Interest in Securities of the Subject Company

    Regulation M-A Item 1008

    (a) Securities ownership. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “The Voting Agreement”


    “Special Factors—Interests of the Directors and Officers of the Company in the Merger”

    “Other Important Information Regarding the Company—Security Ownership of Certain Beneficial Owners and Management”

    “Other Important Information Regarding the Sycamore Entities”

    Annex D: Voting Agreement

    (b) Securities transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Other Important Information Regarding the Company—Prior Public Offerings”

    “Other Important Information Regarding the Company—Certain Transactions in the Shares of Common Stock”

     

    Item 12.

    The Solicitation or Recommendation

    Regulation M-A Item 1012(d) and (e)

    (d) Intent to tender or vote in a going-private transaction. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Intent to Vote in Favor of the Merger”

    “The Voting Agreement”

    “The Special Meeting—Vote Required”

    “The Special Meeting—The SP Investors’ Obligation to Vote in Favor of the Merger”

    Annex A: Agreement and Plan of Merger

    Annex D: Voting Agreement

    (e) Recommendation of others. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Position of the Sycamore Entities as to the Fairness of the Merger, Purposes and Reasons of the Sycamore Entities for the Merger”

    “Special Factors—Intent to Vote in Favor of the Merger”

    “The Merger Agreement Proposal”

     

    Item 13.

    Financial Information

    Regulation M-A Item 1010(a) through (b)

    (a) Financial statements. The audited consolidated financial statements of the Company for the fiscal years ended August 31, 2024 and 2023 are incorporated herein by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2024, filed on October 15, 2024 (see “Item 8—Financial Information” therein) and the unaudited condensed consolidated financial statements of the Company for the quarterly period ended February 28, 2025, are incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended February 28, 2025, filed on April 8, 2025 (see “Item 1—Condensed Consolidated Financial Statements” therein).


    The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Special Factors—Certain Unaudited Prospective Financial Information”

    “Special Factors—Certain Effects of the Merger”

    “Other Important Information Regarding the Company—Book Value per Share”

    “Where You Can Find More Information”

    (b) Pro forma information. Not applicable.

     

    Item 14.

    Persons/Assets, Retained, Employed, Compensated or Used

    Regulation M-A Item 1009

    (a) – (b) Solicitations or recommendations; Employees and corporate assets. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Questions and Answers About the Special Meeting and the Merger”

    “Special Factors—Background of the Merger”

    “Special Factors—Purpose and Reasons of the Company for the Merger; Recommendation of the Board”

    “Special Factors—Interests of the Executive Officers and Non-Employee Directors of the Company in the Merger”

    “Special Factors—Fees and Expenses”

    “The Special Meeting—Solicitation of Proxies; Payment of Solicitation Expenses”

     

    Item 15.

    Additional Information

    Regulation M-A Item 1011(b) and (c)

    (b) Golden Parachute Compensation. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:

    “Summary Term Sheet”

    “Special Factors—Certain Effects of the Merger”

    “Special Factors—Interests of the Executive Officers and Non-Employee Directors of the Company in the Merger”

    “The Merger Agreement—Treatment of Company Stock Awards and Employee Purchase Plans”

    “The Merger-Related Compensation Proposal”

    Annex A: Agreement and Plan of Merger

    (c) Other material information. The information set forth in the Proxy Statement, including all annexes thereto, is incorporated herein by reference.

     

    Item 16.

    Exhibits

    Regulation M-A Item 1016(a) through (d), (f) and (g)

    (a)(1) Preliminary Proxy Statement of Walgreens Boots Alliance, Inc. (the “Proxy Statement”) (included in the Schedule 14A filed concurrently with the SEC and incorporated herein by reference).

    (a)(2) Form of Proxy Card (included in the Proxy Statement and incorporated herein by reference).

    (a)(3) Letter to WBA Stockholders (included in the Proxy Statement and incorporated herein by reference).

    (a)(4) Notice of Special Meeting of Stockholders (included in the Proxy Statement and incorporated herein by reference).


    (a)(5) Current Report on Form 8-K, dated March 6, 2025 (included in Schedule 14A filed on March 6, 2025 and incorporated herein by reference).

    (a)(6) W Worldwide / W Connect Transaction Page (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(7) W Connect Weekly Friday Post from Tim Wentworth, Chief Executive Officer (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(8) Senior Leader Meeting Presentation, dated March 6, 2025 (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(9) Corporate LinkedIn Post, dated March 6, 2025 (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(10) LinkedIn Repost from Tim Wentworth, Chief Executive Officer, dated March 6, 2025 (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(11) LinkedIn Repost from Walgreens, dated March 6, 2025 (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(12) Walgreens Customer-Facing Transaction Overview (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(13) B2B Reactive Email Response (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(14) CareCentrix CEO Team Member Email, dated March 6, 2025 (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(15) CEO Message to Team Members, dated March 6, 2025 (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(16) Partner Email (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(17) Shields CEO Team Member Email, dated March 6, 2025 (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(18) Shields Health Solutions Partner Email (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(19) U.S. Regulator / Government Relationship Manager Email (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(20) VillageMD Team Member Communications, dated March 6, 2025 (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(21) Summit Health and CityMD Follow-Up Memo (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(22) Village Medical Follow-Up Memo (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).


    (a)(23) Investor / Analyst Email – Courtesy Note (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(24) Team Member FAQ (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(25) Store Manager Toolkit: Customer FAQ/Q&A—Store Employee Talking Points (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(26) Tim Wentworth, Video Message to Team Members (Transcript), dated March 6, 2025 (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(27) U.S. Town Hall – Transcript, dated March 7, 2025 (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(28) U.S. Town Hall – Presentation, dated March 7, 2025 (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(29) INTERNATIONAL B2B Stakeholder and Brand Partner Letter—Ireland, (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(30) INTERNATIONAL B2B Stakeholder and Brand Partner Letter (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(31) INTERNATIONAL Government Stakeholder Letter Ireland (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(32) INTERNATIONAL Government Stakeholder Letter UK (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(33) INTERNATIONAL Internal Email to Team Members (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(34) INTERNATIONAL LinkedIn Repost from Boots, dated March 7, 2025 (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(35) SENIOR LEADERS TOOLKIT – OVERVIEW AND Q&A (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(36) INTERNATIONAL Store Manager Message and Q&A (included in Schedule 14A filed on March 7, 2025 and incorporated herein by reference).

    (a)(37) INTERNATIONAL Union Letter Ireland (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(38) INTERNATIONAL Union Letter (included in Schedule 14A filed on March  7, 2025 and incorporated herein by reference).

    (a)(39) International Customer Service Materials and Q&A (included in Schedule 14A filed on March 10, 2025 and incorporated herein by reference).

    (a)(40) Current Report on Form 8-K, dated March 6, 2025 (included in Schedule 14A filed on March 10, 2025 and incorporated herein by reference).


    (a)(41) Supplemental Slides to the Investor Presentation, dated March 11, 2025 (included in Schedule 14A filed on March 11, 2025 and incorporated herein by reference).

    (a)(42) INTERNATIONAL Franchise Letter – Opticians (included in Schedule 14A filed on March  11, 2025 and incorporated herein by reference).

    (a)(43) International Team Member Balcony Briefing Video Transcript (included in Schedule 14A filed on March 12, 2025 and incorporated herein by reference).

    (a)(44) Walgreens W Connect Reminder for Team Members, dated March 13, 2025 (included in Schedule 14A filed on March  13, 2025 and incorporated herein by reference).

    (a)(45) Tim Wentworth, CEO 3/14/25 Update to Team Members on Walgreens W Connect, dated March 14, 2025 (included in Schedule 14A filed on March 14, 2025 and incorporated herein by reference).

    (a)(46) No7 Beauty Company B2B Stakeholder and Brand Partner Letter (included in Schedule 14A filed on March  17, 2025 and incorporated herein by reference).

    (a)(47) Anthony Hemmerdinger (Managing Director, Boots UK and Ireland) Weekly Vlog to Team Members Script, dated March 19, 2025 (included in Schedule 14A filed on March 19, 2025 and incorporated herein by reference).

    (b)(1) Real Estate Financing Commitment Letter, dated March  6, 2025, by and among inter alios, Blazing Star Merger Sub, Inc., UBS AG, Stamford Branch, Wells Fargo Bank, National Association.

    (b)(2) Preferred Equity Commitment Letter, dated March  6, 2025, by and between Blazing Star Merger Sub, Inc. and GoldenTree Asset Management LP.

    (b)(3) Bridge Commitment Letter, dated March  6, 2025, by and among Blazing Star Merger Sub, Inc. and UBS AG, Stamford Branch.

    (b)(4) Shields Commitment Letter, dated March 6, 2025, by and among inter alios, Blazing Star Merger Sub, Inc., HPS Investment Partners, LLC, Goldman Sachs Asset Management, L.P. and JPMorgan Chase Bank, N.A.

    (b)(5) Amended and Restated International Commitment Letter, dated March  27, 2025, by and among inter alios, Blazing Star Merger Sub, Inc., JP Morgan Chase Bank, N.A., JPMorgan Chase Bank, N.A. London Branch, J.P. Morgan Securities plc, Goldman Sachs Bank USA, UBS AG London Branch, Citibank, N.A. London Branch, Citicorp North America, Inc., Deutsche Bank AG New York Branch, Deutsche Bank AG Cayman Islands Branch, Deutsche Bank Securities Inc., Wells Fargo Bank, National Association, Wells Fargo Bank, National Association, London Branch, Wells Fargo Securities, LLC, Mizuho Bank, Ltd., PNC Bank, National Association, PNC Financial Services UK Ltd, PNC Capital Markets LLC, Royal Bank of Canada, The Bank of Nova Scotia, The Bank of Nova Scotia, London Branch, CIBC World Markets Corp., Canadian Imperial Bank of Commerce, Citizens Bank, N.A., The Toronto-Dominion Bank, New York Branch, TD Bank, N.A., TD Securities USA (LLC), BNP Paribas, BNP Paribas Securities Corp., Fifth Third Bank, National Association, Truist Bank and U.S. Bank National Association.

    (b)(6) Factoring Commitment Letter, dated March  6, 2025, by and between Blazing Star Merger Sub, Inc and Wells Fargo Bank, National Association.

    (b)(7) Amended and Restated USR ABL Commitment Letter, dated March 27, 2025, by and among inter alios, Blazing Star Merger Sub, Inc., Wells Fargo Bank, National Association, Citigroup Global Markets Inc., Deutsche Bank AG New York Branch, Deutsche Bank Securities Inc., Goldman Sachs Bank USA, JPMorgan Chase Bank, N.A., UBS AG, Stamford Branch, UBS Securities LLC, Mizuho Bank, Ltd., PNC Bank, National


    Association, PNC Capital Markets LLC, Royal Bank of Canada, CIBC World Markets Corp., Canadian Imperial Bank of Commerce, Citizens Bank, N.A., Fifth Third Bank, National Association, Fifth Third Securities, Inc., The Bank of Nova Scotia, TD Bank, N.A., Truist Bank, Truist Securities, Inc., U.S. Bank National Association, BNP Paribas, BNP Paribas Securities Corp., Regions Bank, and Regions Capital Markets, A Division of Regions Bank.

    (c)(1)* Discussion Materials, dated October  8, 2024, prepared by Centerview for the Board of Directors.

    (c)(2)* Discussion Materials, dated October 24, 2024, prepared by Centerview for the Board of Directors.

    (c)(3)* Discussion Materials, dated December 4, 2024, prepared by Centerview for the Board of Directors.

    (c)(4)* Discussion Materials, dated December 11, 2024, prepared by Centerview for the Transaction Committee of the Board of Directors.

    (c)(5)* Discussion Materials, dated December  18, 2024, prepared by Centerview for the Transaction Committee of the Board of Directors.

    (c)(6)* Discussion Materials, dated December  23, 2024, prepared by Centerview for the Transaction Committee of the Board of Directors.

    (c)(7)* Discussion Materials, dated February 4, 2025, prepared by Centerview for the Transaction Committee of the Board of Directors and the Board of Directors.

    (c)(8)* Discussion Materials, dated February 9, 2025, prepared by Centerview for the Board of Directors.

    (c)(9)* Discussion Materials, dated February  11, 2025, prepared by Centerview for the Transaction Committee of the Board of Directors.

    (c)(10)* Discussion Materials, dated February  13, 2025, prepared by Centerview for the Board of Directors.

    (c)(11)* Discussion Materials, dated February 26, 2025, prepared by Centerview for the Transaction Committee of the Board of Directors.

    (c)(12)* Discussion Materials, dated February  28, 2025, prepared by Centerview for the Board of Directors.

    (c)(13)* Discussion Materials, dated February 28, 2025, prepared by Morgan Stanley for the Board of Directors.

    (c)(14)* Discussion Materials, dated March 6, 2025, prepared by Centerview for the Board of Directors.

    (c)(15)* Discussion Materials, dated March 6, 2025, prepared by Morgan Stanley for the Board of Directors.

    (c)(16) Opinion of Centerview Partners LLC, dated March  6, 2025 (incorporated herein by reference to Annex B of the Proxy Statement).

    (c)(17) Opinion of Morgan Stanley & Co. LLC, dated March 6, 2025 (incorporated herein by reference to Annex C of the Proxy Statement).

    (d)(1) Agreement and Plan of Merger, dated as of March 6, 2025, by and among Walgreens Boots Alliance, Inc., Blazing Star Merger Sub, Inc. and Blazing Star Parent, LLC (incorporated herein by reference to Annex A of the Proxy Statement).

    (d)(2) Voting Agreement, dated March 6, 2025, by and among Walgreens Boots Alliance, Inc., Blazing Star Parent, LLC, Stefano Pessina and Alliance Santé Participations S.A. (incorporated herein by reference to Annex D of the Proxy Statement).


    (d)(3) Reinvestment Agreement, dated March 6, 2025, by and among Blazing Star Parent, LLC, Stefano Pessina and Alliance Santé Participations S.A. (incorporated herein by reference to Annex E of the Proxy Statement).

    (d)(4) Form of Divested Asset Proceed Rights Agreement (incorporated herein by reference to Exhibit A to Annex A of the Proxy Statement).

    (d)(5) Equity Commitment Letter, dated March 6, 2025, by and among Sycamore Partners III, L.P., Sycamore Partners III-A, L.P., Sycamore Partners Wing Co-Invest, L.P., Blazing Star Parent, LLC, Blazing Star Shields Direct Parent, LLC, and Blazing Star IA Parent, LLC.

    (d)(6) Limited Guaranty, dated as of March 6, 2025, by and among Sycamore Partners III, L.P., Sycamore Partners III-A, L.P. and Walgreens Boots Alliance, Inc.

    (d)(7) Interim Investors Agreement, dated March 6, 2025, by and among Sycamore Partners III, L.P., Sycamore Partners III-A, L.P., Sycamore Partners Wing Co-Invest, L.P., Blazing Star Parent, LLC, Blazing Star Merger Sub, Inc., Stefano Pessina and Alliance Santé Participations S.A. (incorporated herein by reference to Exhibit 99.(r) of Schedule 13D/A, filed on March 7, 2025 by Alliance Santé Participations S.A., Stefano Pessina and NewCIP II S.a r.l.)

    (f) Section 262 of the General Corporation Law of the state of Delaware.

    107 Filing Fee Table.

     

    *

    Certain portions of this exhibit have been redacted and separately filed with the SEC pursuant to a request for confidential treatment.


    SIGNATURES

    After due inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: April 14, 2025

     

    WALGREENS BOOTS ALLIANCE, INC.
    By:   /s/ Tim Wentworth
        Name: Tim Wentworth
        Title:  Chief Executive Officer
    BLAZING STAR PARENT, LLC
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:   President
    BLAZING STAR MERGER SUB, INC.
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  President
    SYCAMORE PARTNERS III, L.P.
    By: Sycamore Partners III GP, L.P., its general
    partner
    By: Sycamore Partners III GP, Ltd., its general
    partner
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  Director
    SYCAMORE PARTNERS III-1, L.P.
    By: Sycamore Partners III GP, L.P., its general
    partner
    By: Sycamore Partners III GP, Ltd., its general partner
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  Director


    SYCAMORE PARTNERS WING CO-INVEST,
    L.P.
    By: Sycamore Partners III GP, L.P., its general
    partner
    By: Sycamore Partners III GP, Ltd., its general
    partner
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  Director
    SYCAMORE PARTNERS III GP, L.P.
    By: Sycamore Partners III GP, Ltd., its general
    partner
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  Director
    SYCAMORE PARTNERS III GP, LTD.
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  Director
    BLAZING STAR CCX SUPERCO, INC.
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title: President
    BLAZING STAR IA PARENT, LLC
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  President
    BLAZING STAR SHIELDS SUPERCO II, LLC
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  President
    BLAZING STAR INVESTORS, LLC
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  President


    BLAZING STAR BOOTS SUPERCO (JERSEY)
    LIMITED
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  President
    BLAZING STAR RETAIL BLOCKER BUYER,
    LLC
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  President
    BLAZING STAR OFFICE BLOCKER BUYER,
    LLC
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  President
    BLAZING STAR DC BLOCKER BUYER, LLC
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  President
    BLAZING STAR EXCLUDED PROPERTY
    BLOCKER BUYER, LLC
    By:   /s/ Stefan L. Kaluzny
        Name: Stefan L. Kaluzny
        Title:  President
    ALLIANCE SANTÉ PARTICIPATIONS S.A.
    By:   /s/ Simone Retter
        Name: Simone Retter
        Title:  Président (Chairman)
    By:   /s/ Stefano Pessina
        Name: Stefano Pessina
        Title:  Administrateur (Director)
    STEFANO PESSINA
    By:   /s/ Stefano Pessina
        Name: Stefano Pessina
    Get the next $WBA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/29/25 8:49:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/15/24 5:45:26 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/2/24 6:40:23 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

      For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

      9/12/23 10:44:21 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

      2/28/25 7:36:45 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Leerink Partners initiated coverage on Walgreens Boots Alliance with a new price target

      Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00

      2/26/24 8:28:07 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance downgraded by HSBC Securities

      HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce

      2/20/24 10:23:30 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      5/9/25 4:05:42 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      5/8/25 5:20:44 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Amendment: SEC Form SCHEDULE 13D/A filed by Walgreens Boots Alliance Inc.

      SCHEDULE 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      4/29/25 9:57:03 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/29/25 8:49:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Director Lederer John Anthony

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/18/25 5:58:32 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Director Huffines Robert Luther

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/18/25 5:56:27 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Walgreens Committed to Supporting Rite Aid Customers and Employees

      Walgreens is offering recruitment events for employees and no-hassle prescription transfers for customers impacted by Rite Aid transitions In light of Rite Aid's recent bankruptcy filing, Walgreens is committed to assisting Rite Aid customers and employees who are impacted by store closures in their local community. For customers who want to transfer their prescriptions to Walgreens: We recognize the trust patients have placed in their Rite Aid pharmacists, and Walgreens is here to continue that care with compassion and consistency. Walgreens is dedicated to meeting patients' needs for continued access to trusted, high-quality pharmacy and health services in communities across the countr

      5/9/25 6:46:00 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Debuts PharmStart to Strengthen the Tech to Pharmacist Pipeline

      First-of-its-kind program aims to reduce pre-requisite costs, which remain common barriers for pharmacy technicians looking to pursue a PharmD degree. Walgreens, the nation's largest independent community pharmacy provider, has teamed up with Guild, the leading talent development company, to launch PharmStart, a first-of-its-kind, fully funded online education program designed to help eligible team members meet the prerequisite requirements for pharmacy school. The program aims to eliminate barriers to pursuing a PharmD degree, tapping into a new pool of talent while also addressing critical challenges in the pharmacist talent pipeline. This press release features multimedia. View the full

      4/23/25 6:30:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025

      Walgreens is calling on the public to help in the fight against prescription drug abuse by participating in National Prescription Drug Take Back Day on Saturday, April 26th, 2025. Drug take-back days are reserved annually for the safe disposal of unwanted, unused, or expired medications. Walgreens has more than 1,500 kiosks across 46 states and Washington, D.C. These kiosks are a convenient way to ensure medications are not accidentally or intentionally misused. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421063789/en/Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025 This public

      4/21/25 12:13:00 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      10/18/24 12:45:41 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

      SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

      8/20/24 4:05:58 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      2/13/24 5:17:30 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Financials

    Live finance-specific insights

    See more

    $WBA
    Leadership Updates

    Live Leadership Updates

    See more
    • Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

      Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

      4/8/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

      Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional

      2/6/25 8:30:00 PM ET
      $COR
      $WBA
      Other Pharmaceuticals
      Health Care
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Suspends Quarterly Dividend as Company Continues Disciplined Execution Against Strategic Priorities

      Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors is suspending the company's cash dividend historically paid to stockholders on a quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with the company's broader long-term turnaround efforts. This change in capital allocation is aimed at strengthening WBA's balance sheet by reducing debt over time and improving free cash flow, as the company works toward achieving a retail pharmacy-led turnaround underpinned by a sustainable economic model. The company's cash needs over the next several years, including with respect to litigation and debt refinancing,

      1/30/25 4:55:00 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

      Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

      10/7/24 8:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Appoints Two New Leaders to its Retail and Customer Experience Team

      Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release

      8/16/24 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Super Micro Computer Inc. to Join the Nasdaq-100 Index® Beginning July 22, 2024

      NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc

      7/12/24 8:00:00 PM ET
      $NDAQ
      $SMCI
      $WBA
      Investment Bankers/Brokers/Service
      Finance
      Computer Manufacturing
      Technology